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K e y  M e s s a g e s 
1. Oral mucositis (OM) is common among 
paediatric patients receiving chemotherapy. 
2. Paediatric patients who are neutropaenic, with 
high levels of anxiety, or with a history of OM 
have a greater risk and an earlier onset of OM.
3. OM has negative effects on clinical outcomes and 
the patient’s life, including on oral function and 
quality of life.
Oral mucositis in paediatric patients after 
chemotherapy for cancer
Introduction
Oral mucositis (OM) can aggravate the paediatric 
patients’ clinical condition and elicit multiple 
debilitating oral symptoms that irrevocably alter 
patients’ quality of life.1,2 Nonetheless, the full 
spectrum of pathogenesis and factors in the 
development of OM remains poorly understood, in 
particular in the paediatric cancer population. This 
study aimed to determine the factors associated with 
OM in paediatric patients undergoing chemotherapy 
for cancer, and to compare the outcomes in paediatric 
patients with and without OM.
Methods
This was a multi-centre, prospective, observational 
cohort study conducted from November 2007 to 
November 2009 in a university-affiliated hospital 
and two regional hospitals in Hong Kong. This study 
was approved by the Institutional Review Boards 
of the hospitals, and was conducted in accordance 
with the Declaration of Helsinki. Written informed 
parental consent was obtained for each subject 
before enrolment. A total of 88 boys and 52 girls aged 
6 to 18 (mean, 11.8; standard deviation [SD], 3.3) 
years who underwent stomatotoxic chemotherapy 
for cancer were recruited through convenience 
sampling. Most (56%, n=78) were diagnosed with 
haematological malignancies, and most (28%, n=39) 
were treated with adriamycin-based chemotherapy.
 Subjects were asked to use a daily diary to 
complete the Chinese version of the mouth and 
throat soreness (MTS)-related questions of the 
Oral Mucositis Daily Questionnaire from the start 
Hong Kong Med J 2014;20(Suppl 7):S4-8
HHSRF project number: 05060471
WY Ip *, JB Epstein, V Lee, HL Yuen, R Li, DR Thompson, WB Goggins, KKF Cheng
of chemotherapy (day 1) to day 14, the Chinese 
version of the State Anxiety Scale for Children on 
day 1, and the Oropharyngeal Mucositis Quality of 
Life Scale (OMQoL) at baseline, day 7, and day 14. 
Demographic and clinical data were collected from 
interviews and subjects’ medical records. Binary 
and ordinal logistic regression analyses were used to 
assess the relation between potential factors and risk 
of OM occurrence. The Cox proportional hazards 
regression model was used to determine the effect 
of potential factors on time in days to onset of OM. 
Differences in proportions of subjects manifesting 
adverse clinical and patient-reported outcomes 
between subjects with, and without OM and by 
severity of OM were compared using the Chi-square 
test, one-way ANOVA, and multi-level modelling 
techniques.
Results
Incidence, onset, and severity of oral 
mucositis
Overall, 41% (n=57) of paediatric patients developed 
OM (Table 1). Of these, 23% (n=32) reported a 
maximum MTS score of 2 (non-severe OM), and 
18% (n=25) reported a maximum MTS score of 3-4 
(severe OM). The mean time to onset of OM was 4.7 
(SD, 2.7; range, 2-9; 95% confidence interval [CI], 
4.0-5.4) days after the start of chemotherapy, with 
a mean duration of 6.3 (SD, 4; range, 1-13; 95% CI, 
5.2-7.4) days and with the peak at day 7.5 (SD, 2.6; 
range, 4-11; 95% CI, 6.8-8.2). The mean area under 
the curve (AUC) MTS score across 14 days was 16.9 
(SD, 6.5; range, 2.5-28.5; 95% CI, 15.1-18.6). 
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Factors associated with oral mucositis
Paediatric patients with and without OM were similar 
with regard to age, gender, oral care, traditional 
Chinese medicine consumption, renal functional 
status, use of growth factor, and extent of nausea 
and vomiting (P>0.25, Table 2). Paediatric patients 
with OM were more likely to have haematological 
malignancies and a low consumption of sweet food 
than those without OM (P<0.25). The univariate 
analysis revealed that a history of OM, a higher level 
of anxiety, ≥1 neutropaenia, and ≥1 liver toxicity 
significantly increased the risk of developing OM 
(P<0.05). 
 A history of OM, sweet food consumption, 
anxiety, cancer diagnosis, absolute neutrophil 
count, and aspartate aminotransferase to alanine 
aminotransferase ratio all had values of P<0.25 in the 
univariate models and were included as candidate 
variables for the multivariate model, adjusting for 
potential confounding factors of the chemotherapy 
regimen. In the multivariate model, only a history of 
OM (adjusted odds ratio [OR], 3.94; 95% CI, 1.49-
10.39), a higher level of anxiety (adjusted OR, 1.46; 
95% CI, 1.23-1.73), and grade 1-2 (adjusted relative 
risk [RR], 4.59; 95% CI, 1.81-11.66) and 3-4 (adjusted 
RR, 9.19; 95% CI, 1.83-46.29) neutropaenia were 
significantly associated with a higher probability of 
OM, after controlling for the chemotherapy regimen 
(P<0.01).
 The AUC MTS score was categorised into 
three ordinal subgroups of 0 (n=55), 1-11.5 (n=39), 
and ≥12 (n=46). The results of these subgroups were 
consistent with the binary logistic regression model. 
A history of OM (adjusted OR, 2.43; 95% CI, 1.14-
5.18, P=0.02), a higher level of anxiety (adjusted 
OR, 1.37; 95% CI, 1.20-1.55, P<0.001), and grade 1-2 
(adjusted OR, 2.93; 95% CI, 1.41-6.10, P=0.004) and 
3-4 (adjusted OR, 8.69; 95% CI, 2.12-35.69, P=0.003) 
neutropaenia were significantly associated with a 
higher category of AUC MTS, after adjusting for 
the chemotherapy regimen. These variables were 
also independent predictors of the time in days to 
the onset of OM, after controlling for chemotherapy. 
On Cox regression analysis, the hazard ratios of a 
history of OM and anxiety were 1.90 (95% CI, 1.01-
3.59, P=0.04) and 1.27 (95% CI, 1.18-1.37, P<0.001), 
respectively. The hazard ratios of grade 1-2 and 3-4 
neutropaenia were 1.86 (95% CI, 1.08-3.07, P<0.01) 
and 3.08 (95% CI, 2.27-6.40, P<0.01), respectively.
Oral mucositis and its related activity 
limitations
The incidence of a maximum MTS-activity 
limitations score of 2 (non-severe limitations) and 
TABLE 1.  Characteristics of paediatric patients with or without oral mucositis (OM) after chemotherapy
Variable No. (%) of patients
Absence of OM (mouth and throat 
soreness [MTS] score of<2) [n=83]
Presence of OM (MTS 
score of ≥2) [n=57]
Total 
(n=140)
Age (years)
6-12 43 (51.8) 32 (56.1) 75 (53.6)
13-18 40 (48.2) 25 (43.9) 65 (46.4)
Gender
Boys 53 (63.9) 35 (61.4) 88 (62.9)
Girls 30 (36.1) 22 (38.6) 52 (37.1)
Education level (n=135)
Primary 1-3 17 (21.2) 6 (10.9) 23 (17)
Primary 4-6 34 (42.5) 19 (34.5) 53 (39.3)
Secondary 1-3 19 (23.8) 21 (38.2) 40 (29.6)
Secondary 4-7 10 (12.5) 9 (16.4) 19 (14.1)
Cancer diagnosis
Solid tumours 42 (50.6) 20 (35.1) 62 (44.3)
Haematological malignancies 41 (49.4) 37 (64.9) 78 (55.7)
Cancer regimen
Etoposide-based regimen 15 (18.1) 3 (5.3) 18 (12.9)
Methotrexate-based regimen 11 (13.3) 14 (24.6) 25 (17.9)
Cytarabine-based regimen 9 (10.8) 4 (7.0) 13 (9.3)
Adriamycin-based regimen 22 (26.5) 17 (29.8) 39 (27.9)
Other anthracycline-based regimen 7 (8.4) 6 (10.5) 13 (9.3)
Combined etoposide, methotrexate, 
cytarabine and/or adriamycin regimen
19 (22.9) 13 (22.8) 32 (22.9)
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TABLE 2  Factors associated with oral mucositis (OM)
Factors Absence of OM 
(mouth and throat 
soreness [MTS] score 
of<2) [n=83]
Presence of OM 
(MTS score of ≥2) 
[n=57]
Bivariate 
analysis 
(unadjusted 
OR [95% CI])
P value Multivariate binary 
logistic analysis* 
(adjusted OR 
[95% CI])
P value
Patient-related
Age (years) [No. (%) of patients]
6-12 43 (51.8) 32 (56.1) 1.0 (reference) 0.614 - -
13-18 40 (48.2) 25 (43.9) 0.84 (0.43-1.65)
Gender (No. [%] of patients)
Male 53 (63.9) 35 (61.4) 1.0 (reference) 0.768 - -
Female 30 (36.1) 22 (38.6) 1.11 (0.55-2.23)
Cancer diagnosis (No. [%] of patients)
Solid tumours 42 (50.6) 20 (35.1) 1.0 (reference)
Haematological malignancies 41 (49.4) 37 (64.9) 1.90 (0.95-3.8) 0.069 - -
A history of OM (No. [%] of patients)
No 51 (61.4) 25 (43.9) 1.0 (reference) 0.040 3.94 (1.49-10.39) 0.006
Yes 32 (38.6) 32 (56.1) 2.04 (1.03-4.05)
Multivariate ordinal logistic analysis to predict area under the curve (AUC) MTS groups 2.43 (1.14-5.18) 0.02
Cox proportional hazards regression analysis to predict the days to onset of OM (hazard ratio [95% CI]) 1.90 (1.01-3.59) 0.04
No. of tooth brushing per day in the first 5 days 
(mean±SD [range])
1.34±0.6 (1.20-1.48) 1.46±0.6 (1.28-1.63) 1.35 (0.78-2.31) 0.282
No. of saline rinsing per day in the first 5 days 
(mean±SD [range])
0.98±1.3 (0.69-1.30) 1.23±1.4 (0.86-1.60) 1.15 (0.90-1.47) 0.278
Days of sweet food consumption in the first 5 days 
(mean±SD [range])
1.86±1.7 (1.49-2.22) 1.46±1.6 (1.04-1.87) 0.86 (0.69-1.06) 0.155 - -
Days of traditional Chinese medicine consumption 
in the first days (mean±SD [range])
0 0 -
Anxiety level (mean±SD [range]) 15.48±2.9 (14.84-16.11) 18.18±3.4 (17.29-19.08) 1.33 (1.17-1.51) <0.001 1.46 (1.23-1.73) <0.001
Multivariate ordinal logistic analysis to predict AUC MTS groups 1.37 (1.20-1.55) <0.001
Cox proportional hazards regression analysis to predict the days to onset of OM (hazard ratio [95% CI]) 1.27 (1.18-1.37) <0.001
Treatment-related
Cancer regimen (No. [%] of patients)
Etoposide-based regimen 15 (18.1) 3 (5.3) 0.29 (0.07-1.21) 0.091 0.28 (0.05-1.54) 0.143
Methotrexate-based regimen 11 (13.3) 14 (24.6) 1.86 (0.65-5.36) 0.251 1.80 (0.44-7.27) 0.412
Cytarabine-based regimen 9 (10.8) 4 (7.0) 0.65 (0.17-2.56) 0.538 0.34 (0.05-2.52) 0.288
Adriamycin-based regimen 22 (26.5) 17 (29.8) 1.13 (0.44-2.91) 0.801 0.89 (0.24-3.21) 0.853
Other anthracyclines-based regimen 7 (8.4) 6 (10.5) 1.25 (0.34-4.59) 0.734 2.31 (0.39-13.57) 0.355
Combined etoposide, methotrexate, cytarabine 
and/or adriamycin regimen
19 (22.9) 13 (22.8) 1.0 (reference)
Neutropaenia (109/L) [No. (%) of patients]
Grade 0 (≥2) 54 (65.1) 11 (19.3) 1.0 (reference)
Grade 1-2 (1-1.9) 9 (10.8) 16 (28.1) 3.74 (1.75-8.01) 0.001 4.59 (1.81-11.66) 0.001
Grade 3-4 (<0.5-0.9) 20 (24.1) 30 (52.6) 6.24 (1.87-20.79) 0.003 9.19 (1.83-46.29) 0.007
Multivariate ordinal logistic analysis for grade 1-2 neutropaenia to predict AUC MTS groups 2.93 (1.41-6.10) 0.004
Multivariate ordinal logistic analysis for grade 3-4 neutropaenia to predict AUC MTS groups 8.69 (2.12-35.69) 0.003
Cox proportional hazards regression analysis for grade 1-2 neutropaenia to predict the days to onset of OM (hazard ratio [95% CI]) 1.86 (1.08-3.07) <0.01
Cox proportional hazards regression analysis for grade 3-4 neutropaenia to predict the days to onset of OM (hazard ratio [95% CI]) 3.08 (2.27-6.40) <0.01
Liver toxicity (IU/L) [No. (%) of patients]
Grade 0 (≤1.25) 37 (44.6) 8 (14.0) 1.0 (reference)
Grade 1-2 (1.26-5) 37 (44.6) 34 (59.6) 4.25 (1.74-10.40) 0.002 - -
Grade 3-4 (5.1- >10) 9 (10.8) 15 (26.3) 7.71 (2.50-23.76) <0.001 - -
Renal toxicity (µmol/L) [No. (%) of patients]
Grade 0 (≤1.25 x106) 83 (100) 57 (100) Not estimable -
Acute emetogenicity [No. (%) of patients]
Day 1
Grade 0 (without nausea & vomiting) 59 (71.1) 40 (70.2) 1.0 (reference)
Grade 1-2 (nausea only to vomiting 1-5 
episodes/day)
23 (27.7) 17 (29.8) 1.09 (0.52-2.30) 0.820
Grade 3-4 (vomiting ≥6->10 episodes/day) 1 (1.2) 0 0 1.00
Day 2
Grade 0 (without nausea & vomiting) 53 (63.9) 40 (70.2) 1.0 (reference)
Grade 1-2 (nausea only to vomiting 1-5 
episodes/day)
25 (30.1) 14 (24.6) 1.26 (0.28-5.58) 0.763
Grade 3-4 (vomiting ≥6->10 episodes/day) 5 (6.0) 3 (5.3) 0.93 (0.19-4.50) 0.932
Use of cytokine anytime in the first 5 days (No. [%] 
of patients) 
No 81 (97.6) 56 (98.2) 1.0 (reference) 0.793 - -
Yes 2 (2.4) 1 (1.8) 0.72 (0.06-8.17)
* Likelihood ratio test for the overall model (Chi-square=56.48, P<0.001)
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a maximum MTS-activity limitations score of 3-4 
(severe limitations) in swallowing, drinking, eating, 
speaking, and sleeping resulting from OM ranged 
from 18% (n=25) to 35% (n=49). Approximately 
39% (22 out of 57) of paediatric patients with OM 
reported at least two simultaneous non-severe or 
severe activity limitations, and 25% (14 out of 57) 
reported having all five non-severe or severe activity 
limitations resulting from OM simultaneously. 
Between 64% and 80% (n=16-20) of paediatric 
patients with severe OM reported severe oral 
activity limitations. The presence of severe sleeping 
problems resulting from OM was reported in 60% 
(n=15) of paediatric patients with severe OM.
Oral mucositis and quality of life
All OMQoL subscale scores of paediatric patients 
with an AUC MTS of ≥12 were significantly lower 
than those with an AUC MTS of 0 or 1-11.5 at all the 
time points (P<0.001). All OMQoL subscale scores 
of all three AUC MTS subgroups varied significantly 
between days 1, 7, and 21 (P<0.001). Of those with 
an AUC MTS of ≥12, 41% (n=19) to 85% (n=39) had 
a drop in the OMQoL subscale scores to at least 10 
points from the baseline, respectively.
Oral mucositis and clinical outcomes 
A weight loss of ≥2 kg was common among paediatric 
patients with a maximum MTS of 3-4 (30%, n=7) or 
an AUC MTS of ≥12 (21%, n=9) [Table 3]. The mean 
weight loss increased with increasing maximum MTS 
or AUC MTS score, reaching a mean loss of 1.64 (SD, 
0.5) kg and 1.50 (SD, 1.0) kg in paediatric patients 
with a maximum MTS of 3-4 and AUC MTS of ≥12, 
respectively. In addition, for paediatric patients with 
a maximum MTS of 3-4 or AUC MTS of ≥12, fluid 
replacement, analgesic use, and oral or intravenous 
antibiotics were more common (P<0.001). Fever also 
increased with increasing maximum MTS or AUC 
MTS scores. No difference was observed for oral or 
systemic infections among the subgroups. None of 
the paediatric patients had dose modification, dose 
delay, or hospitalisation due to OM.
Discussion
The incidence of OM in paediatric patients 
receiving chemotherapy was moderately high (41%). 
Factors significantly associated with an increased 
incidence, early onset, and severe OM included 
a history of OM, severe neutropaenia, and a high 
anxiety level; this relationship was independent 
of the type of chemotherapy. These factors may 
play a role in the aetiology of OM in a synergistic 
manner, reflecting the multifactorial nature of OM. 
The higher ORs of neutropaenia suggest that it 
may be the most important risk factor. This finding 
is consistent with our understanding of indirect 
cytotoxicity and the biological process involved 
in the pathogenesis of OM.2 A decrease in the 
neutrophil count may result in an impaired ability 
to protect against oral mucosal damage, and may 
affect the proliferation of oral epithelial cells.3 In 
*	 Post-hoc	comparisons	of	mean	weight	loss:	MTS	scores	of	3-4	and	2	were	significantly	higher	than	MTS	score	of	≤1, whereas AUC MTS of ≥12 and 
1-11.5	were	significantly	higher	than	AUC	MTS	of	0
TABLE 3.  Relationship between the severity of oral mucositis (OM) and clinical outcomes
Variable Absence of 
mucositis
Presence of mucositis P value Area under curve (AUC) MTS P value
Mouth 
and throat 
soreness 
(MTS) score 
of ≤1 (n=83)
MTS score 
of 2 (n=32)
MTS score 
of 3-4 
(n=25)
0 (n=55) 1-11.5 
(n=39)
≥12 (n=46)
Weight loss of ≥2kg (n=90)
 No. (%) of patients 5 (13.2) 5 (17.9) 7 (30.4) 0.246 1 (5.0) 7 (25.9) 9 (21.4) 0.171
Mean±SD (range)* 0.63±1.4 
(0.17-1.09)
1.30±0.9
 (0.95-1.65)
1.64±0.5 
(1.41-1.87)
0.002 -0.16±1.4
(-0.81-0.49)
1.44±0.6 
(1.27-1.62)
1.50±1.0 
(1.09-1.91)
<0.001
Supportive care (No. [%] of patients)
Fluid replacement (n=137) 30 (37.5) 16 (50.0) 22 (88.0) <0.001 12 (21.8) 21 (53.8) 35 (76.1) <0.01
Oral or intravenous antibiotics (n=129) 54 (68.4) 21 (75.0) 20 (90.9) 0.103 33 (62.3) 24 (68.6) 38 (92.7) 0.003
Use of analgesics 2 (2.4) 20 (62.5) 21 (84.0) <0.001 1 (1.8) 9 (23.1) 33 (71.7) <0.001
Hospitalisation for OM 0 0 0 - 0 0 0 -
Associated conditions (No. [%] of patients)
Dose delay 0 0 0 - 0 0 0 -
Dose modification 0 0 0 - 0 0 0 -
Fever (n=139) 21 (25.0) 9 (28.0) 18 (72.0) <0.001 10 (18.2) 15 (39.5) 23 (50.0) 0.003
Oral or systemic infections (n=139) 5 (6.1) 2 (6.2) 5 (20.0) 0.130 2 (3.6) 4 (10.5) 6 (13.0) 0.218
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addition, neutropaenic patients are at increased 
risk for microbial colonisation of damaged mucosal 
surfaces, resulting in increased pro-inflammatory 
cytokines in oral mucosa, which may aggravate 
OM.2 Nevertheless, neutropaenia is largely non-
modifiable and therefore there is limited opportunity 
to intervene in the aetiopathophysiological process 
and the development of OM and thus limited 
direct clinical value in this finding. Consequently, 
routine assessment of neutrophil level prior to 
commencement of chemotherapy for high-risk 
groups is important for aggressive prophylactic 
OM intervention and treatment, or to consider 
adjustments to the target dosage of chemotherapy to 
prevent the occurrence and severity of OM.
 The independent effect of a history of OM 
is plausible, considering the genetic susceptibility 
factors in the inflammatory response which influences 
cytokine expression and the mucosal ulcerative 
process, and hence individual predisposition to OM 
in each cycle of chemotherapy, but this risk factor 
is non-modifiable. Nevertheless, this association 
warrants further studies. Our findings suggested 
that an increased anxiety level was a risk factor for 
OM. It is probable that oral immunologic function 
and pro-inflammatory cytokine levels are influenced 
by anxiety.4 Avoidance of this risk factor by psycho-
educational or cognitive-behavioural intervention 
may allay some of the increase in incidence and 
severity of OM. In this study, we did not observe 
an independent effect of peak liver toxicity on OM 
in the final model, despite univariate associations. 
Age, gender, creatinine value, acute emetogenicity, 
and use of growth factor were not significantly 
associated with OM, nor were oral care, sweet food, 
or traditional Chinese medicine consumption.
 The prevalence of a multitude of co-existing 
oral functional limitations reported by paediatric 
patients with OM was 39%, suggesting that OM is 
a symptomatic and comorbid condition.5 Eating and 
swallowing difficulties were the most severe oral 
functional limitations during OM, probably related 
to the potentially compromised muscular movement 
during swallowing, resulting from mouth and 
throat soreness, which made eating and swallowing 
unpleasant. Severe sleeping problems resulting from 
OM were reported in 60% of paediatric patients with 
severe OM. The mechanism by which OM influences 
patients’ sleeping is possibly due to intense mouth/
throat pain and drooling.
 Most paediatric patients with severe OM 
recorded a drop in the OMQoL subscale scores to 
at least 10 points from the baseline. The reduction 
in body weight associated with OM was significant, 
probably owing to decreased intake and nutritional 
deficiencies resulting from mouth/throat pain 
and difficulty in swallowing. In addition, fluid 
replacement, analgesic usage, and the administration 
of oral or intravenous antibiotics were significantly 
associated with severe OM. Contributing to the 
increased use of fluid replacement and analgesics 
in patients with severe OM is the combination of 
pain and oral symptoms that compromise muscular 
movement, making chewing and swallowing difficult 
and unpleasant, and thereby reducing patients’ will 
and desire to eat and drink. Fever also increased with 
an increasing severity of OM; such an association 
may be attributed to neutropaenia and infections.
Conclusions 
Paediatric patients who are neutropaenic, with a 
history of OM, or with high levels of anxiety have a 
higher incidence of OM, an earlier onset, and more 
severe OM. They often suffer a multitude of intense 
and debilitating impairments of oral function, and 
sleeping difficulties. 
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